- Home
- G vs CNTA Comparison
G vs CNTA Comparison
Compare G & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | G | CNTA |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | Bermuda | United Kingdom |
| Employees | 140000 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.1B |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | G | CNTA |
|---|---|---|
| Price | $32.30 | $39.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $49.50 | $43.17 |
| AVG Volume (30 Days) | ★ 3.1M | 1.0M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | 9.82 | ★ 29.13 |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $2,279,438,000.00 | $15,000,000.00 |
| Revenue This Year | $9.20 | N/A |
| Revenue Next Year | $7.27 | N/A |
| P/E Ratio | $38.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.78 | $10.95 |
| 52 Week High | $48.64 | $40.26 |
Technical Indicators
Market Signals| Indicator | G | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 70.73 |
| Support Level | $28.78 | $39.36 |
| Resistance Level | $32.95 | $40.26 |
| Average True Range (ATR) | 1.35 | 0.11 |
| MACD | 0.37 | -0.15 |
| Stochastic Oscillator | 55.73 | 71.08 |
Price Performance
Historical ComparisonAbout G Genpact Limited
Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.